Strive Health valuation, funding and investors
Strive Health works in value-based kidney care solutions, based in Denver, United States. Founded in 2018, it has about 628 employees.
- Last round
- Series D · $550M · Sep 2025
- Valuation at last round
- $1.80B
- Headcount
- 628 · up
- Grade
- A
- Founded
- 2018
Strive Health valuation today
VCMC values Strive Health at $2.4B today, with a range of $1.5B to $2.8B and a grade of A. The valuation starts from its last funding round, a Series D round in Sep 2025.
Valuation by date (109 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2018 | $9.05M | $3.29M – $24.9M | $12.4M (+37%) | before first round | – | unknown | D | 0% |
| 1 Feb 2018 | $9.29M | $3.38M – $25.5M | $12.7M (+37%) | before first round | – | unknown | D | 0% |
| 1 Mar 2018 | $9.52M | $3.47M – $26.2M | $13.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Apr 2018 | $9.78M | $3.56M – $26.9M | $13.4M (+37%) | before first round | – | unknown | D | 0% |
| 1 May 2018 | $10.0M | $3.65M – $27.6M | $13.8M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jun 2018 | $10.3M | $3.75M – $28.3M | $14.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jul 2018 | $10.6M | $3.85M – $29.1M | $14.5M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2018 | $10.9M | $3.96M – $29.9M | $14.7M (+35%) | before first round | – | unknown | D | 0% |
| 1 Sep 2018 | $11.2M | $4.06M – $30.7M | $14.8M (+32%) | before first round | – | unknown | D | 0% |
| 1 Oct 2018 | $11.5M | $4.17M – $31.5M | $14.9M (+30%) | before first round | – | unknown | D | 0% |
| 1 Nov 2018 | $11.8M | $4.28M – $32.3M | $15.1M (+28%) | before first round | – | unknown | D | 0% |
| 1 Dec 2018 | $12.1M | $4.40M – $33.2M | $15.2M (+26%) | before first round | – | unknown | D | 0% |
| 1 Jan 2019 | $12.4M | $4.52M – $34.1M | $15.3M (+24%) | before first round | – | unknown | D | 0% |
| 1 Feb 2019 | $12.7M | $4.64M – $35.0M | $15.5M (+21%) | before first round | – | unknown | D | 0% |
| 1 Mar 2019 | $13.1M | $4.75M – $35.9M | $15.6M (+19%) | before first round | – | unknown | D | 0% |
| 1 Apr 2019 | $13.4M | $4.88M – $36.8M | $15.7M (+17%) | before first round | – | unknown | D | 0% |
| 1 May 2019 | $13.8M | $5.01M – $37.8M | $15.9M (+15%) | before first round | – | unknown | D | 0% |
| 1 Jun 2019 | $14.1M | $5.15M – $38.8M | $16.0M (+13%) | before first round | – | unknown | D | 0% |
| 1 Jul 2019 | $14.5M | $5.28M – $39.8M | $16.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2019 | $14.7M | $5.33M – $40.2M | $16.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2019 | $14.8M | $5.38M – $40.6M | $16.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2019 | $14.9M | $5.43M – $41.0M | $16.6M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2019 | $15.1M | $5.48M – $41.4M | $16.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2019 | $15.2M | $5.53M – $41.7M | $16.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2020 | $15.3M | $5.58M – $42.1M | $17.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2020 | $15.5M | $5.63M – $42.5M | $17.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2020 | $15.6M | $5.68M – $42.9M | $17.4M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2020 | $15.7M | $5.73M – $43.3M | $17.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2020 | $15.9M | $5.78M – $43.6M | $17.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2020 | $16.0M | $5.84M – $44.0M | $17.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jul 2020 | $16.2M | $5.89M – $44.4M | $18.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2020 | $16.3M | $5.94M – $44.8M | $18.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2020 | $16.5M | $6.00M – $45.2M | $18.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2020 | $16.6M | $6.05M – $45.6M | $18.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2020 | $16.8M | $6.11M – $46.1M | $18.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2020 | $16.9M | $6.16M – $46.5M | $18.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2021 | $21.8M | $7.94M – $59.9M | $24.3M (+11%) | before first round | 73 | unknown | D | 0% |
| 1 Feb 2021 | $22.0M | $8.01M – $60.4M | $24.5M (+11%) | before first round | 73 | unknown | D | 0% |
| 1 Mar 2021 | $22.2M | $8.07M – $60.9M | $24.6M (+11%) | before first round | 73 | unknown | D | 0% |
| 17 Mar 2021 | $1.0B | $657M – $2.3B | $1.5B (+50%) | after a round | 73 | unknown | C | 0% |
| 1 Apr 2021 | $1.0B | $657M – $2.3B | $1.5B (+47%) | after a round | 73 | flat | C | 0% |
| 1 May 2021 | $1.1B | $657M – $2.3B | $1.5B (+43%) | after a round | 73 | flat | C | 0% |
| 1 Jun 2021 | $1.1B | $657M – $2.3B | $1.5B (+38%) | after a round | 73 | flat | C | 0% |
| 1 Jul 2021 | $1.1B | $657M – $2.3B | $1.5B (+33%) | after a round | 73 | flat | C | 0% |
| 1 Aug 2021 | $1.2B | $657M – $2.3B | $1.5B (+29%) | after a round | 73 | flat | C | 0% |
| 1 Sep 2021 | $1.2B | $657M – $2.3B | $1.5B (+24%) | after a round | 73 | flat | C | 0% |
| 1 Oct 2021 | $1.2B | $657M – $2.3B | $1.5B (+20%) | after a round | 73 | flat | C | 0% |
| 1 Nov 2021 | $1.3B | $657M – $2.3B | $1.5B (+16%) | after a round | 73 | flat | C | 0% |
| 1 Dec 2021 | $1.3B | $657M – $2.3B | $1.5B (+12%) | after a round | 73 | flat | C | 0% |
| 1 Jan 2022 | $1.4B | $657M – $2.3B | $1.5B (+9%) | after a round | 73 | flat | C | 0% |
| 1 Feb 2022 | $1.9B | $890M – $3.1B | $2.0B (+9%) | after a round | 290 | growing | C | 0% |
| 1 Mar 2022 | $2.0B | $890M – $3.1B | $2.0B (+3%) | after a round | 290 | growing | C | 0% |
| 1 Apr 2022 | $2.0B | $895M – $3.1B | $2.0B (0%) | after a round | 290 | growing | C | 0% |
| 1 May 2022 | $2.0B | $906M – $3.1B | $2.0B (0%) | after a round | 290 | growing | C | 0% |
| 1 Jun 2022 | $2.0B | $917M – $3.1B | $2.0B (0%) | after a round | 290 | growing | C | 0% |
| 1 Jul 2022 | $2.0B | $928M – $3.1B | $2.0B (0%) | after a round | 290 | growing | C | 0% |
| 1 Aug 2022 | $2.0B | $939M – $3.1B | $2.0B (0%) | after a round | 290 | growing | B | 0% |
| 1 Sep 2022 | $2.0B | $951M – $3.1B | $2.0B (0%) | after a round | 290 | growing | B | 0% |
| 1 Oct 2022 | $2.0B | $962M – $3.1B | $2.0B (0%) | after a round | 290 | growing | B | 0% |
| 1 Nov 2022 | $2.0B | $641M – $3.1B | $2.0B (0%) | after a round | 290 | unknown | C | 0% |
| 1 Dec 2022 | $2.0B | $615M – $3.1B | $2.0B (0%) | after a round | 290 | unknown | C | 0% |
| 1 Jan 2023 | $2.0B | $588M – $3.1B | $2.0B (0%) | after a round | 290 | unknown | C | 0% |
| 1 Feb 2023 | $2.0B | $563M – $3.1B | $2.0B (0%) | after a round | 290 | unknown | C | 0% |
| 1 Mar 2023 | $2.0B | $541M – $3.1B | $2.0B (0%) | after a round | 290 | unknown | C | 0% |
| 1 Apr 2023 | $2.2B | $1.0B – $3.3B | $2.2B (0%) | after a round | 400 | growing | B | 0% |
| 1 May 2023 | $2.2B | $1.0B – $3.3B | $2.2B (0%) | after a round | 400 | growing | B | 0% |
| 1 Jun 2023 | $1.6B | $1.1B – $2.9B | $2.1B (+30%) | after a round | 400 | growing | B | 0% |
| 1 Jul 2023 | $1.6B | $1.1B – $2.9B | $2.1B (+27%) | after a round | 400 | growing | B | 0% |
| 1 Aug 2023 | $1.7B | $1.1B – $2.9B | $2.1B (+24%) | after a round | 400 | growing | B | 0% |
| 1 Sep 2023 | $1.7B | $1.1B – $2.9B | $2.1B (+22%) | after a round | 400 | unknown | B | 0% |
| 1 Oct 2023 | $1.8B | $1.2B – $3.0B | $2.1B (+22%) | after a round | 470 | up | B | 0% |
| 1 Nov 2023 | $1.8B | $1.2B – $3.0B | $2.1B (+19%) | after a round | 470 | up | B | 0% |
| 1 Dec 2023 | $1.8B | $1.2B – $3.0B | $2.1B (+16%) | after a round | 470 | up | B | 0% |
| 1 Jan 2024 | $1.9B | $1.2B – $3.0B | $2.1B (+13%) | after a round | 470 | up | B | 0% |
| 1 Feb 2024 | $2.0B | $1.2B – $3.1B | $2.2B (+11%) | after a round | 510 | up | B | 0% |
| 1 Mar 2024 | $2.0B | $1.2B – $3.1B | $2.2B (+8%) | after a round | 520 | up | B | 0% |
| 1 Apr 2024 | $2.1B | $1.2B – $3.1B | $2.2B (+5%) | after a round | 520 | up | B | 0% |
| 1 May 2024 | $2.1B | $1.2B – $3.1B | $2.2B (+3%) | after a round | 520 | up | B | 0% |
| 1 Jun 2024 | $2.2B | $1.2B – $3.1B | $2.2B (0%) | after a round | 520 | up | B | 0% |
| 1 Jul 2024 | $2.2B | $1.2B – $3.1B | $2.2B (0%) | after a round | 520 | up | B | 0% |
| 1 Aug 2024 | $2.2B | $1.2B – $3.1B | $2.2B (0%) | after a round | 520 | up | B | 0% |
| 1 Sep 2024 | $2.2B | $1.1B – $3.1B | $2.2B (0%) | after a round | 520 | up | B | 0% |
| 1 Oct 2024 | $2.2B | $1.1B – $3.1B | $2.2B (0%) | after a round | 520 | up | B | 0% |
| 1 Nov 2024 | $2.2B | $1.1B – $3.1B | $2.2B (0%) | after a round | 520 | up | B | 0% |
| 1 Dec 2024 | $2.2B | $1.1B – $3.1B | $2.2B (0%) | after a round | 520 | up | B | 0% |
| 1 Jan 2025 | $2.2B | $1.1B – $3.1B | $2.2B (0%) | after a round | 520 | up | B | 0% |
| 1 Feb 2025 | $2.2B | $1.1B – $3.1B | $2.2B (0%) | after a round | 520 | up | B | 0% |
| 1 Mar 2025 | $2.2B | $1.1B – $3.1B | $2.2B (0%) | after a round | 520 | up | B | 0% |
| 1 Apr 2025 | $2.2B | $1.1B – $3.1B | $2.2B (0%) | after a round | 520 | up | B | 0% |
| 1 May 2025 | $2.2B | $716M – $3.1B | $2.2B (0%) | after a round | 520 | flat | C | 0% |
| 1 Jun 2025 | $2.2B | $648M – $3.1B | $2.2B (0%) | after a round | 520 | flat | C | 0% |
| 1 Jul 2025 | $2.2B | $618M – $3.1B | $2.2B (-1%) | after a round | 527 | flat | C | 0% |
| 1 Aug 2025 | $2.2B | $591M – $3.1B | $2.2B (-1%) | after a round | 543 | flat | C | 0% |
| 1 Sep 2025 | $2.2B | $562M – $3.1B | $2.2B (-2%) | after a round | 543 | flat | C | 0% |
| 10 Sep 2025 | $1.8B | $1.6B – $2.7B | $2.3B (+30%) | after a round | 543 | flat | A | 0% |
| 1 Oct 2025 | $1.8B | $1.6B – $2.7B | $2.3B (+28%) | after a round | 543 | flat | A | 0% |
| 1 Nov 2025 | $1.9B | $1.6B – $2.7B | $2.4B (+26%) | after a round | 554 | flat | A | 0% |
| 1 Dec 2025 | $1.9B | $1.6B – $2.7B | $2.4B (+23%) | after a round | 554 | flat | A | 0% |
| 1 Jan 2026 | $2.0B | $1.6B – $2.7B | $2.4B (+20%) | after a round | 554 | flat | A | 0% |
| 1 Feb 2026 | $2.0B | $1.6B – $2.7B | $2.4B (+17%) | after a round | 554 | flat | A | 0% |
| 1 Mar 2026 | $2.1B | $1.6B – $2.8B | $2.4B (+16%) | after a round | 599 | up | A | 0% |
| 1 Apr 2026 | $2.1B | $1.6B – $2.8B | $2.4B (+13%) | after a round | 599 | up | A | 0% |
| 1 May 2026 | $2.2B | $1.6B – $2.8B | $2.4B (+11%) | after a round | 635 | up | A | 0% |
| 1 Jun 2026 | $2.2B | $1.6B – $2.8B | $2.4B (+8%) | after a round | 635 | up | A | 0% |
| 1 Jul 2026 | $2.3B | $1.6B – $2.8B | $2.4B (+6%) | after a round | 635 | up | A | 0% |
| 1 Aug 2026 | $2.3B | $1.6B – $2.8B | $2.4B (+3%) | after a round | 630 | up | A | 0% |
| 1 Sep 2026 | $2.4B | $1.6B – $2.8B | $2.4B (+1%) | after a round | 630 | up | A | 0% |
| 1 Oct 2026 | $2.4B | $1.6B – $2.8B | $2.4B (0%) | after a round | 628 | up | A | 0% |
| 24 Oct 2026 | $2.4B | $1.5B – $2.8B | $2.4B (0%) | after a round | 628 | up | A | 0% |
Key facts about Strive Health
- Founded
- 2018
- Headquarters
- Denver, United States
- Employees
- about 628 +13% in a year
- Total raised
- $856M
- Funding rounds
- 4
- Last round
- Series D Sep 2025
Strive Health was founded in 2018 by Chris Riopelle and Will Stokes.
Strive Health funding history
Strive Health has 4 funding rounds on record, from Mar 2021 to Sep 2025, $856M in total. The latest disclosed valuation is $1.80B post-money (Series D, Sep 2025).
Series D 9 Sep 2025
Led by New Enterprise Associates, Hercules Capital; with CVS Health Ventures, CapitalG, Echo Health Ventures, Town Hall Ventures, Redpoint Ventures, BlackRock, Inc..
Sources: townhallventures.com, fiercehealthcare.com, mobihealthnews.com and 1 more
$550M
$1.80B post-money
Debt 9 Sep 2025no round page
Led by Hercules Capital.
Sources: echohealthventures.com, strivehealth.com, fiercehealthcare.com and 1 more
Amount undisclosed
Series C 31 May 2023
Led by New Enterprise Associates; with CVS Health Ventures, CapitalG, Echo Health Ventures, Town Hall Ventures, Ascension, Redpoint Ventures.
Sources: strivehealth.com, strivehealth.com, healio.com and 1 more
$166M
Series B 16 Mar 2021
Led by CapitalG; with Redpoint Ventures, New Enterprise Associates, Town Hall Ventures, Ascension, Echo Health Ventures.
Sources: finsmes.com, strivehealth.com, ascensionventures.org
$140M
Strive Health investors
9 investors have backed Strive Health; CapitalG, New Enterprise Associates and Hercules Capital led at least one round.
- CapitalG lead, 3 rounds
- New Enterprise Associates lead, 3 rounds
- Redpoint Ventures 3 rounds
- CVS Health Ventures 2 rounds
- BlackRock, Inc.
What Strive Health does
Strive Health works in health care services, with 13 recorded offerings and customers in healthcare.
Strive Health, LLC is an American healthcare company engaged in value-based kidney care solutions, including chronic kidney disease and end-stage renal disease management. The company provides population health management, nephrology services, kidney transplant coordination, and kidney disease-specific care plans. Strive Health also operates a technology platform that integrates healthcare data from multiple sources to support real-time care planning and a multispecialty, nurse practitioner-led care team. The company serves health systems, payors, nephrologists, and medical groups across the United States, and its case management and population health programs are accredited by the National Committee for Quality Assurance (NCQA) and its technology platform is certified by HITRUST.
Description from Veridion's company data.
Products and services
- Value-Based Kidney Care Solutions
- Population Health Management Services
- Nephrology Care Delivery Services
- Kidney Disease-Specific Care Plan Development
- Kidney Transplant Coordination Services
- Multispecialty Nurse Practitioner Care Delivery
- Technology-Enabled Care Intervention Delivery
- Healthcare Data Integration and Insights Generation
- Flexible Value-Based Payment Arrangement Services
- Provider Network Integration Services
- Patient Journey Support Services
- Clinical Model Implementation Services
- Integrated Care Delivery System Development
Markets
- Healthcare
Technology
- Healthcare Data Integration for Real-Time Insights
Certifications
- NCQA accredited
- HITRUST certified
Business model
- Business-to-Business
- Service Provider
- Healthcare
- Enterprise
Industry codes (NAICS)
- 621498 All Other Outpatient Care Centers 70% match
- 621999 All Other Miscellaneous Ambulatory Health Care Services 30% match
Questions about Strive Health
What is Strive Health worth?
Valuation $2.4B (range $1.5B to $2.8B), as of 24 Oct 2026. The last disclosed valuation was $1.80B (Series D, Sep 2025).
Has Strive Health raised money?
Strive Health has 4 funding rounds on record, from Mar 2021 to Sep 2025, $856M in total. The latest disclosed valuation is $1.80B post-money (Series D, Sep 2025).
Who has invested in Strive Health?
CapitalG, New Enterprise Associates, Hercules Capital, Echo Health Ventures, Redpoint Ventures and Town Hall Ventures, and 3 more. Lead investors include CapitalG, New Enterprise Associates and Hercules Capital.
How many people work at Strive Health?
About 628, up 13% over the last year. Headcount grew from 73 in Jan 2021 to 628 in Sep 2026.
What does Strive Health do?
Strive Health works in health care services, with 13 recorded offerings and customers in healthcare. Its main offerings are value-based kidney care solutions, population health management services and nephrology care delivery services.
When was Strive Health founded, and where is it based?
Strive Health was founded in 2018 and is based in Denver, United States. It has about 628 employees, up 13% over the last year.